Advanced search
Publication Cover
Expert Review of Hematology Volume 6, 2013 - Issue 5
Submit an article Journal homepage
215
Views
24
CrossRef citations to date
0
Altmetric
Reviews

Thrombosis in pediatric cancer: identifying the risk factors to improve care

Uma Athale
Pages 599-609 | Published online: 10 Jan 2014

References

  • Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2013. Canadian Cancer Society, Toronto, ON, Canada (2013).
  • Marina N. Long term survivors of childhood cancer: the medical consequences of cure. Pediatr. Clin. North. Am. 44, 1021–1042 (1997).
  • Raffini L, Huang Y-S, Witmer C, Feudtner C. Dramatic increase in venous thromboembolism in U.S. Children’s Hospitals from 2001-2007. Pediatrics 124, 1001–1008 (2009).
  • O’Brien SH, Klima J, Termuhlen AM, Kelleher KJ. Venous thromboembolism and adolescent and young adult oncology inpatients in US Children’s Hospitals, 2001 to 2008. J. Pediatr. 159, 133–137 (2011).
  • Caruso V, Lacoviello L, Castelnuovo ADet al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 patients. Blood 108, 2216–2222 (2006).
  • Athale UH, Siciliano S, Thabane Let al. Epidemiology and clinical risk factors predisposing to thromboembolism in children with cancer. Pediatr. Blood Cancer 51, 792–797 (2008).
  • Paz-Priel I, Long L, Helman LJ, Mackall CL, Wayne AS. Thromboembolic events in children and young adults with pediatric sarcoma. J. Clin. Oncol. 25, 1519–1524 (2007).
  • Mitchell LG, Andrew M, Hanna Ket al.; Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase Group (PARKAA). A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) study. Cancer 97, 508–516 (2003).
  • Ruud E, Holmstrome H, De Lange C, Hogstad EM, Wesenberg F. Low dose warfarin or the prevention of central line-associated thrombosis in children with malignancy – a randomized controlled study. Acta. Paediatrica 95, 1053–1059 (2006).
  • Bick RL. Cancer-associated thrombosis. N. Engl. J. Med. 349, 1091–2000 (2003).
  • Falanga A, Marchetti M. Venous thromboembolism in hematologic malignancies. J. Clin. Oncol. 27, 4848–4857 (2009).
  • Kuderer NM, Ortel T, Francis CW. Impact of venous thromboembolism and anticoagulat on cancer and cancer survival. J. Clin. Oncol. 27, 4902–4911 (2009).
  • Lyman GH. Venous thromboembolism in the patient with cancer. Focus on burden of disease and benefits of thromboprophylaxis. Cancer 117, 1334–1349 (2011).
  • Sood SL. Cancer-associated thrombosis. Curr. Opin. Hematol. 16, 378–385 (2009).
  • Heit JA. Cancer and venous thromboembolism. Scope of the problem. Cancer control 12(1), 5–10 (2005).
  • Athale UH, Chan AK. Thrombosis in children with acute lymphoblastic leukemia part I: epidemiology of thrombosis in children with acute lymphoblastic leukemia. Thromb. Res. 111(51), 125–131 (2003).
  • Athale UH, Moghrabi A, Nayiger T, Yves-Line D, Thabane L, Chan AK. von Willebrand factor and thrombin activation in children with newly diagnosed acute lymphoblastic leukemia: an impact of peripheral blasts. Pediatr. Blood Cancer 54, 963–969 (2010).
  • Ruud E, Holmstrom H, Brosstad F, Wesenberg F. Children with acute lymphoblastic leukaemia have high plasma levels of total homocysteine at time of diagnosis. Scand. J. Clin. Lab. Invest. 66, 67–78 (2006).
  • Oner AF, Gurgey A, Kirazli S, Okur H, Tunc B. Changes of hemostatic factors in children with acute lymphoblastic leukemia receiving combined chemotherapy including high dose methyl prednisolone and L-asparaginase. Leuk. Lymphoma 33, 361–364 (1999).
  • Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood 80, 1998–2005 (1992).
  • Andrew M, David M, Adams Met al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian registry of VTE. Blood 83, 1251–1257 (1994).
  • Athale UH, Siciliano SA, Crowther M, Barr RD, Chan AK. Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease. Br. J. Haematol. 129, 803–810 (2005).
  • Grace RF, Dahlberg SE, Neuberg Det al. The frequency and management of asparaginase-related thrombosis in pediatric and adult patients with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Consortium protocols. Br. J. Haematol. 152, 452–459 (2011).
  • Pui CH, Campana D, Pei Det al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Eng J. Med. 360, 2730–2741 (2009).
  • Pui CH, Pei D, Campana Det al. Improved prognosis for older adolescents with acute lymphoblastic leukemia. J. Clin. Oncol. 29, 386–391 (2011).
  • Moricke A, Reiter A, Zimmerman Met al. Risk-adjusted therapy for acute lymphoblastic leukemia can reduce therapy burden and increase survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 111, 4477–4489 (2008).
  • Sifontes MT, Nuss R, Hunger SP, Wilimas J, Jacobson LJ, Manco-Johnson MJ. The factor V Leiden mutation in children with cancer and thrombosis. Br. J. Haematol. 96, 484–489 (1997).
  • Wermes C, von Depka Prondzinski M, Lichtinghagen R, Barthels M, Welte K, Sykora KW. Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters. Eur. J. Pediatr. 158(3), S143–S146 (1999).
  • Audino AN, Yeager ND, Asti L, Miao Y, O’Brien SH. Length of stay and treatment-related complications are similar in pediatric and AYA patients with bone sarcoma in United States Children’s Hospitals. Pediatr. Blood Cancer 60, 415–419 (2013).
  • SPaneesha, McManus A, Arya Ret al. Frequency, demographic and risk (according to tumor type or site)of cancre-assocaited thrombosis among patients seen at outpatient DVT clinics. Thromb. Haemost. 103, 338–343 (2010).
  • Setty BA, O’Brien SH, Kerlin BA. Pedaitric venous thromboembolism in the United States: a tertiary care complication of chronic diseases. Pediatr. Blood Cancer 59, 258–264 (2012).
  • Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in hospitalized neutropenic cancer patients. J. Clin. Oncol. 24, 484–490 (2006).
  • Mereu L, Tateo S, Klersy C, Martinotti Gabellotti E, Polatti F. Stratification of venous thromboembolism risk in ovarian cancer patients during chemotherapy. Int. J. Gynecol. Cancer 19, 79–83 (2009).
  • Vu LT, Nobuhara KK, Lee H, Farmer DL. Determination of risk factors for deep venous thrombosis in hospitalized children. J. Pediatr. Surg. 43, 1095–1099 (2008).
  • Kahn SR. How I treat postthrombotic syndrome. Blood 114, 4624–4631 (2009).
  • Manco-Johnson M, Beckman MG, Goldenberg NAet al. Risk of postthrombotic syndrome development in children with extermitydeep venous thrombosis: results of the US centers of disease control and prevention pediatric thrombosis and hemostasis centers. Blood 114, 4000 (2009).
  • Tuckuviene R, Christensen AL, Chan ACK, Athale U. Body mass index and thromboembolism in children with hematological malignancies. Pediatric. Blood Cancer 59, 320–322 (2012).
  • Raffini L. Thrombophilia in children: who to test, how, when and why? Am. So. Hematology Edu. Program. 2008, 228–235 (2008).
  • Elhasid R, Lanir N, Sharon Ret al. Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul. Fibrinolysis. 12, 367–370 (2001).
  • Kishi S, Griener J, Cheng Cet al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J. Clin. Oncol. 21, 3084–3091 (2003).
  • Stiakaki E, Germanakis I, Sfyridaki C, Katzilakis N, Danilatou V, Kalmanti M. Prevalence of Factor V Leiden and other thrombophilic traits among Cretan children with malignancy. Pediatr. Blood Cancer 44, 386–389 (2005).
  • Nowak-Gottl U, Wermes C, Junker Ret al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood 93, 1595–1599 (1999).
  • Mauz-Korholz C, Junker R, Gobel U, Nowak-Gottl U. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols). Thromb. Haemost. 83, 840–843 (2000).
  • Revel-Vilk S, Yacobovich J, Tamary Het al. Risk factors for central venous catheter thrombotic complications in children and adolescents with cancer. Cancer 116, 4197–4205 (2010).
  • Athale UH, Chan AKC. Thromboembolic complications in pediatric hematologic malignancies. Semin. Thromb. Hemos. 33(4), 416–426 (2007).
  • Tallman MS, Altman JK. How I treat acute promyelocytic leukemia. Blood 114, 5126–5135 (2009).
  • Choudhry A, DeLoughery TG. Bleeding and thrombosis in acute promyelocytic leukemia. Am. J. Hematol. 87, 596–603 (2012).
  • Journeycake JM, Buchanan GR. Catheter-related deep vein thrombosis and other catheter complications in children with cancer. J. Clin. Oncol. 24(28), 4575–4580 (2006).
  • Deitcher SR, Gajjar A, Kun L, Heideman RL. Clinically evident venous thromboembolic events in children with brain tumours. J. Pediatr. 145, 848–850 (2004).
  • Tabori U, Beni-Adani L, Dvir Ret al. Risk of venous thromboembolism in pediatric patients with brain tumors. Pediatr. Blood Cancer 43, 633–636 (2004).
  • Kim S, Chung DH. Pediatric solid malignancies: neuroblastoma and Wilms’ tumor. Surg. Clin. North Am. 86(2), 469–487 (2006).
  • Kirkwood I, McCarville M, Baharami A, Shulkin B. [F-18]FDG PET/CT appearance of tumor thrombi in pediatric solid tumors. J. Nucl. Med. 53(1), 2193 (2012).
  • Wang JN, Chen JS, HYet al. Invasion of the cardiovascular system in childhood malignant hepatic tumors. J. Pediatr. Hematol. Oncol. 24, 436–439 (2002).
  • Massicotte MP, Dix D, Monagle P, Adams M, Andrew M. Central venous catheter related thrombosis in children: analysis of the Canadian Registry of Venous Thromboembolic Complications. J. Pediatr. 133, 770–776 (1998).
  • Glaser DW, Medeiros D, Rollins N, Buchanan GR. Catheter-related thrombosis in children with cancer. J. Pediatr. 138, 255–259 (2001).
  • Knofler R, Siegert E, Lauterbach Iet al. Clinical importance of prothrombotic risk factors in pediatric patients with malignancy–impact of central venous lines. Eur. J. Pediatr. 158(3), S147–S150 (1999).
  • Fratino G, Molinari AC, Parodi Set al. Central venous catheter-related complications in children with oncological/hematological diseases: an observational study of 418 devices. Ann. Oncol. 16, 648–654 (2005).
  • McLean TW, Fisher CJ, Snively BM, Chauvenet AR. Central venous lines in children with lesser risk acute lymphoblastic leukemia: optimal type and timing of placement. J. Clin. Oncol. 23, 3024–3029 (2005).
  • Male C, Chait P, Andrew Met al. Central venous line-related thrombosis in children: association with central venous line location and insertion technique. Blood 101, 4273–4278 (2003).
  • Baskin JL, Pui CH, Reiss Uet al. Management of occlusion and thrombosis associated with long-term indwelling central venous catheters. Lancet 374, 159–169 (2009).
  • Sovinz P, Urban C, Lackner H, Kerbl R, Schwinger W, Dornbusch H. Tunneled femoral central venous catheters in children with cancer. Pediatrics 107(6), E104 (2001).
  • Fratino G, Molinari AC, Mazzola Cet al. Prospective study of indwelling central venous catheter-related complications in children with broviac or clampless valved catheters. J. Pediatr. Hematol. Oncol. 24(8),657–661 (2002).
  • Kalmanti M, Germanakis J, Stiakaki Eet al. Prophylaxis with urokinase in pediatric oncology patients with central venous catheters. Pediatr. Hematol. Oncol. 19(3), 173–179 (2002).
  • Dillon PW, Jones GR, Bagnall-Reeb HA, Buckley JD, Wiener ES, Haase GM. Prophylactic urokinase in the management of long-term venous access devices in children: a Children’s Oncology group study. J. Clin. Oncol. 22(13), 2718–2723 (2004).
  • Cesaro S, Tridello G, Cavaliere Met al. Prospective, randomized trial of two different modalities of flushing central venous catheters in pediatric patients with cancer. J. Clin. Oncol. 27(12), 2059–2065 (2009).
  • Chung BH, Ma ES, Khong PL, Chan GC. Inherited thrombophiliac factors do not increase central lines in children with malignancy. Pediatr. Blood Cancer 51(4), 509–512 (2008).
  • Ociepa T, Maloney E, Urasinski T, Sawicki M. Thrombotic complications of tunneled central venous catheter blockage in children with malignancy. J. Pediatr. Hematol. Oncol. 32(2), 88–92 (2010).
  • Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb. Res. 118, 555–558 (2006).
  • Lee AY, Levine MN. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin. Thromb. Hemost. 25, 137–145 (1999).
  • Ramot Y, Nyska A. Drug induced thrombosis-experimental, clinical and mechanistic considerations. Toxicologic. Pathol. 35, 208–225 (2007).
  • Athale UH, Chan AK. Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy. Thromb. Res. 111, 199–212 (2003).
  • Wiernikowaski J, Athale UH. Thromboembolic complications in children with cancer. Thromb. Res. 118, 137–152 (2006).
  • Mitchell LG, Sutor AH, Andrew M. Hemostasis in childhood acute lymphoblastic leukemia: coagulopathy induced by disease and treatment. Semin. Thromb. Hemost. 21, 390–401 (1995).
  • Mills PJ, Parker B, Jones Vet al. The effects of standard anthracycline-based chemotherapy on soluble ICAM-1 and vascular endothelial growth factor levels in breast cancer. Clin. Cancer Res. 10, 4998–5003 (2004).
  • Walsh J, Wheeler HR, Geczy CL. Modulation of tissue factor on human monocytes by cisplatin and adriamycin. Br. J. Haematol. 81, 480–488 (1992).
  • Boles JC, Williams JC, Hollingsworth RMet al. Anthracycline treatment of the human monocytic leukemia cell lineTHP1 increases phosphotidylserine exposure and tissue factor activity. Thromb. Res. 129, 197–203 (2012).
  • Togna GI, Togna AR, Franconi M, Caprino L. Cisplatin triggers platelet activation. Thromb. Res. 99, 503–509 (2000).
  • Ozturk G, Ozsoylu S, Gursel T. Effects of methylprednisolone on FVIII:C and vWF levels. Eur. J. Haematol. 53, 119–120(1994).
  • Sartori MT, Rigotti P, Marchini Fet al. Plasma fibrinolytic capacity in renal transplant recipients: effect of steroid-free immunosuppression therapy. Transplantation 75, 994–998 (2003).
  • Patrassi GM, Sartori MT, Livi Uet al. Impairment of fibrinolytic potential in long-term steroid treatment after heart transplantation. Transplantation 64, 1610–1614 (1997).
  • Raffini L, Trinarchi T, Beliveau J, Davis D. Thromboprophylaxis in a pediatric hospital: a patient safety and quality improvement initiative. Pediatrics 127, e1326–e1332 (2011).
  • Jackson PC, Morgan JM. Perioperative thromboprophylaxos in children: development of a guideline for management. Paediatr. Anaesth. 18, 478–487 (2008).
  • Lipay NV, Dmitriev VV, Borisenok MB. Thrombotic complications during cancer treatment in children. Exp. Oncol. 29, 231–235 (2007).
  • Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy associated venous thromboembolism in a prospective observational study. Cancer 104, 2822–2829 (2005).
  • Ay C, Simanek R, Vormittag Ret al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from Vienna Cancer and Thrombosis Study (CATS). Blood 112, 2703–2708 (2008).
  • Ay C, Vormittag R, Dunkler Det al. D-dimer and prothrombin fragment 1+2 predict venous thromboembolism in patients with cancer: results from Vienna Cancer and Thrombosis Study J. Clin. Oncol. 27, 4124–4129 (2009).
  • Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of predictive model for chemotherapy associated thrombosis. Blood 111, 4902–4907 (2008).
  • Ay C, Dunkler D, Marosi Cet al. Prediction of venous thromboembolism in cancer patients. Blood 116, 5377–5382(2010).
  • Mitchell L, Lambers M, Flege Set al. Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study. Blood 115, 4999–5004 (2010).

Website

  • Howlader N, Noone AM, Krapcho Met al. US Department of Health and Human Services: SEER Cancer statistics review, 1975–2010, National Cancer Institute, Bethesda, MD. Based on November 2012 SEER data submitted posted for the SEER Website, April 2013. http://seer.cancer.gov/csr/1975_2010/

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.